Status:
COMPLETED
Strategy of UltraProtective Lung Ventilation With Extracorporeal CO2 Removal for New-Onset Moderate to seVere ARDS
Lead Sponsor:
European Society of Intensive Care Medicine
Conditions:
Moderate Acute Respiratory Distress Syndrome
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
Pathophysiological, experimental and clinical data suggest that an '"ultraprotective" mechanical ventilation strategy may further reduce VILI and ARDS-associated morbidity and mortality. Severe hyperc...
Detailed Description
Over the past few decades, highly significant progress has been made in understanding the pathophysiology of the acute respiratory distress syndrome (ARDS). Recognition of ventilation-induced lung inj...
Eligibility Criteria
Inclusion
- Mechanical ventilation with expected duration of \>24h
- Moderate ARDS according to the Berlin definition(16) PaO2/FiO2: 200-100 mmHg, with PEEP ≥ 5 cmH2O
Exclusion
- Age \<18 years
- Pregnancy
- Decompensated heart insufficiency or acute coronary syndrome
- Severe COPD
- Major respiratory acidosis PaCO2\>60 mmHg
- Acute brain injury
- Severe liver insufficiency (Child-Pugh scores \>7) or fulminant hepatic failure
- Heparin-induced thrombocytopenia
- Contraindication for systemic anticoagulation
- Patient moribund, decision to limit therapeutic interventions
- Catheter access to femoral vein or jugular vein impossible
- Pneumothorax
- Platelet \<50 G/l
Key Trial Info
Start Date :
November 1 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 30 2017
Estimated Enrollment :
95 Patients enrolled
Trial Details
Trial ID
NCT02282657
Start Date
November 1 2015
End Date
July 30 2017
Last Update
August 4 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
selected ICUs for the pilot phase
Different Locations and Several Countries, Belgium